In recent years, tumor immunotherapy such as anti-PD-1/PD-L1/CTLA-4 monoclonal antibody and chimeric antigen receptor T-cell (CAR-T) immunotherapy has extensively attentioned as an important part of combined therapy (Hilmi et al., 2019). Here, CTLA4 is linked to neoplasm.